Leqvio (Inclisiran) Anesthesia and Perioperative Interaction

What Is Inclisiran and How Does It Work?

Inclisiran is a synthetic small interfering RNA (siRNA) that binds to hepatocyte ASGPR receptors and silences PCSK9 mRNA, reducing PCSK9 protein production and thereby increasing LDL receptor recycling on hepatocyte surfaces. The FDA approved inclisiran sodium (Leqvio) in December 2021 for adults with primary hyperlipidemia or heterozygous familial hypercholesterolemia [1]. Unlike monoclonal antibody PCSK9 inhibitors such as evolocumab or alirocumab, inclisiran acts intracellularly through the RNA-induced silencing complex (RISC) and does not circulate at meaningful concentrations after the first 24 to 48 hours post-injection.

Pharmacokinetic Basics That Drive Perioperative Safety

After a 284 mg subcutaneous injection, plasma inclisiran concentrations peak at roughly 4 hours and decline with a terminal half-life of approximately 9 hours [2]. The drug reaches the liver via ASGPR-mediated endocytosis, where it is retained in hepatocytes as an active RISC complex. Systemic exposure is therefore transient. Because inclisiran is neither a CYP450 substrate nor an inhibitor, co-administration with CYP-metabolized anesthetic agents (propofol, fentanyl, midazolam, ketamine, rocuronium) does not alter plasma levels of either drug [3].

Why the Mechanism Matters for Anesthesia Planning

Traditional drug-interaction concerns in the perioperative period center on three pathways: CYP enzyme competition, plasma protein displacement, and prolonged QTc effects. Inclisiran scores near zero on all three counts. Its low and transient systemic presence after the first day means an operating room team scheduling a patient six weeks or six months after a Leqvio injection is managing a drug that exists almost entirely as an intrahepatic silencing complex, not a circulating molecule subject to classic drug-drug interaction [2].

Does Inclisiran Interact Directly With Anesthetic Agents?

No established pharmacokinetic or pharmacodynamic interaction exists between inclisiran and any approved general, regional, or monitored anesthesia care agent. The FDA prescribing information for Leqvio lists no drug-drug interactions requiring dose adjustment or avoidance [1]. This absence of interactions reflects the drug's siRNA mechanism, which bypasses the enzyme systems that most anesthetic agents depend on for metabolism and clearance.

Specific Anesthetic Agents Reviewed

Propofol is metabolized via UGT1A9 and CYP2B6; inclisiran does not inhibit or induce either enzyme [3]. No dosing change is needed.

Volatile anesthetics (sevoflurane, desflurane, isoflurane) are metabolized partly by CYP2E1 and CYP2A6. Again, inclisiran has no documented effect on these isoforms [4]. Sevoflurane MAC values should not be affected.

Opioids used in the perioperative period, including fentanyl, morphine, and hydromorphone, are CYP3A4 and UGT substrates. Inclisiran does not modulate CYP3A4 activity [1].

Neuromuscular blocking agents such as rocuronium and succinylcholine depend on hepatic or plasma esterase clearance rather than CYP pathways. No interaction with inclisiran has been reported in trial safety data from ORION-9, ORION-10, or ORION-11 [5].

Benzodiazepines used for procedural sedation (midazolam, lorazepam) are CYP3A4 substrates. Inclisiran's label explicitly states no clinically meaningful CYP3A4 interaction [1].

Regional Anesthesia Considerations

Local anesthetics (lidocaine, bupivacaine, ropivacaine) undergo hepatic first-pass metabolism via CYP1A2 and CYP3A4. In patients on inclisiran, hepatic enzyme activity is preserved. The drug silences only PCSK9 mRNA; it does not alter global hepatic CYP expression or hepatic blood flow [3]. A standard nerve block or neuraxial technique therefore requires no modification.

Perioperative Management: Timing and Practical Protocol

Inclisiran's every-six-month dosing schedule simplifies surgical planning considerably. A patient due for their next injection can receive it before or after surgery without clinical concern, because the drug produces no acute cardiovascular or hemostatic effects that would complicate the operative period.

Should You Hold the Dose Before Surgery?

The FDA label for Leqvio contains no instruction to hold the drug before surgery, and no major anesthesiology society guideline (ASA, ESAIC) has issued a perioperative hold recommendation specific to inclisiran [1]. The Society for Cardiovascular Angiography and Interventions position paper on PCSK9 inhibitors from 2022 did not identify inclisiran as requiring a perioperative pause [6].

If a dose happens to fall within 48 hours of a planned surgery, administering it slightly before or slightly after the procedure is clinically acceptable, given that peak plasma concentrations resolve within 24 to 48 hours and the LDL-lowering effect persists for months either way [2].

Cardiovascular Risk Context During Surgery

Patients receiving inclisiran typically carry a high atherosclerotic cardiovascular disease (ASCVD) burden. ORION-10 (N=1,561) showed a 52.3% reduction in LDL-C from baseline at 17 months in patients with established ASCVD already on maximally tolerated statins [7]. These patients may be at elevated perioperative cardiac risk independent of inclisiran use. The 2022 ACC/AHA guideline on perioperative cardiovascular evaluation recommends continuing lipid-lowering therapy through the perioperative period to preserve plaque stability [8]. Abruptly stopping inclisiran would not cause immediate LDL rebound in the short term because the RISC silencing effect persists, but interrupting any LDL-lowering agent before surgery contradicts that ACC/AHA guidance.

Coagulation and Bleeding Risk

Inclisiran does not affect platelet function, coagulation factor synthesis, or thromboelastography parameters. The ORION-9 trial (N=482, heterozygous familial hypercholesterolemia) recorded bleeding adverse events at rates comparable to placebo [9]. Neuraxial anesthesia decisions based on anticoagulation status should account for any concomitant anticoagulant therapy the patient takes, not inclisiran itself.

Hepatic Function, Drug Metabolism, and Inclisiran

Because inclisiran accumulates in hepatocytes, clinicians sometimes ask whether it affects the liver's capacity to metabolize drugs during anesthesia. The answer is no. Inclisiran silences one specific mRNA sequence (PCSK9). It does not reduce hepatic blood flow, impair mitochondrial function, or alter CYP450 enzyme expression [3]. Liver function tests in the ORION trials remained within normal limits for inclisiran-treated patients at rates nearly identical to placebo [5].

Patients With Pre-Existing Hepatic Impairment

The FDA label notes that inclisiran pharmacokinetics were not studied in severe hepatic impairment (Child-Pugh C). Mild-to-moderate hepatic impairment (Child-Pugh A and B) did not meaningfully alter drug exposure in a dedicated PK sub-study [1]. For patients with severe hepatic impairment scheduled for surgery, the anesthesiologist's primary concern remains the impaired hepatic clearance of anesthetic agents themselves, not any interaction with inclisiran.

Renal Impairment Considerations

Inclisiran undergoes nuclease-mediated degradation in tissues; renal excretion of intact drug is minimal. The label indicates that no dose adjustment is required for any degree of renal impairment [1]. This is clinically relevant for perioperative patients who may experience acute kidney injury, because renal status does not alter inclisiran pharmacokinetics in either direction.

Can You Drink Alcohol on Leqvio?

No pharmacokinetic interaction exists between ethanol and inclisiran. Alcohol is metabolized via alcohol dehydrogenase and CYP2E1, neither of which is affected by inclisiran [4]. The FDA label contains no alcohol warning specific to the drug [1].

Indirect Hepatic Concern With Heavy Alcohol Use

The one indirect concern involves patients with alcohol-related liver disease. Heavy, sustained alcohol consumption causes hepatic steatosis, fibrosis, and eventually cirrhosis, all of which reduce the functional hepatocyte mass that inclisiran depends on for ASGPR-mediated uptake. In patients with alcoholic cirrhosis, LDL-lowering efficacy may be reduced and hepatic drug handling generally is impaired. The clinical guidance in that scenario is to address alcohol use disorder, not to avoid inclisiran specifically [10].

Moderate alcohol intake (one to two standard drinks per day) in a patient with normal liver function poses no documented risk with inclisiran. Patients who drink moderately before or after a surgery during which inclisiran is active need no special counseling beyond standard perioperative alcohol guidance from their surgical team.

Drug-Drug Interactions Beyond Anesthesia

Inclisiran has a remarkably clean interaction profile compared to most cardiovascular medications. The FDA-approved label identifies no formal drug interactions requiring dose modification [1]. The ORION-11 phase 3 trial (N=1,617) enrolled patients on statins, ezetimibe, fibrates, and antiplatelet agents; no clinically significant interaction signals emerged in that polypharmacy population over 18 months [11].

Statins

Statins are the most common co-medication for inclisiran patients. Both drugs target LDL-C reduction through complementary mechanisms: statins reduce cholesterol synthesis, while inclisiran reduces PCSK9-mediated LDL receptor degradation. No PK interaction between inclisiran and atorvastatin, rosuvastatin, or simvastatin has been identified [3]. The combination does not increase myopathy risk beyond what statins carry independently.

Anticoagulants and Antiplatelets

Warfarin, direct oral anticoagulants (DOACs), aspirin, and P2Y12 inhibitors are frequently co-prescribed in ASCVD patients. None of these agents are processed by the RISC pathway, and inclisiran does not affect vitamin K-dependent coagulation factor levels [5]. INR monitoring for warfarin patients starting inclisiran is not required by the label. In the perioperative setting, anticoagulant management follows standard bridging or hold protocols based on the anticoagulant itself, not on inclisiran.

Immunosuppressants

Cyclosporine and tacrolimus are substrates of CYP3A4 and P-glycoprotein. Inclisiran does not modulate either pathway [1]. However, cyclosporine inhibits OATP1B1 and OATP1B3 transporters relevant to statin co-therapy. The interaction concern in a transplant patient on a statin plus inclisiran involves the statin and cyclosporine, not inclisiran directly.

QTc Prolongation and Cardiac Monitoring

A specific question in cardiac anesthesia is whether inclisiran contributes to QTc prolongation, which could compound the QT effects of anesthetic agents such as haloperidol, ondansetron, or certain volatile agents at high doses. The ORION-1 phase 2 trial cardiac safety sub-analysis found no evidence of QTc prolongation attributable to inclisiran at any dose [12]. The drug's intrahepatic confinement means no ion channel exposure in cardiomyocytes after the first 48 hours post-injection.

Cardiovascular Outcomes Data

The ORION-4 cardiovascular outcomes trial (NCT03705234) is ongoing, enrolling roughly 15,000 patients, and primary results are expected in 2026 [13]. Interim safety data released through 2024 have not identified any unexpected cardiac signal. Until full outcomes data are published, perioperative cardiac risk assessment should follow standard ASCVD-based algorithms (revised cardiac risk index, Duke Activity Status Index) independent of inclisiran status.

Injection Site and Postoperative Wound Considerations

Inclisiran is administered subcutaneously into the abdomen, upper arm, or thigh. Injection site reactions (erythema, pain, bruising) occurred in 8.2% of inclisiran patients versus 1.8% of placebo in pooled ORION-9/10/11 data [5]. These local reactions are self-limited and do not affect surgical wound healing or sterile technique.

If a patient is hospitalized for a major procedure near the scheduled injection date, the injection can be administered by a nurse while inpatient without sterility concerns beyond standard subcutaneous injection protocol. Delaying the dose by up to three months does not eliminate the LDL-lowering effect, because RISC-mediated PCSK9 silencing persists for several months after a single injection [2].

HealthRX Perioperative Decision Framework for Inclisiran Patients

The following stepwise approach reflects current FDA labeling, ACC/AHA perioperative guidelines, and the pharmacokinetic properties described above.

Step 1. Confirm current inclisiran dosing schedule. Ask the patient when their last injection was given and when the next is due. Document the date in the anesthetic record.

Step 2. Review concomitant cardiovascular medications. Identify any anticoagulants, antiplatelets, or statins that have independent perioperative management requirements. Inclisiran itself requires none.

Step 3. Assess hepatic function. For patients with Child-Pugh B or C hepatic impairment, note that anesthetic agent clearance may be prolonged. Inclisiran PK is not the variable driving this concern.

Step 4. Continue inclisiran through the perioperative period. Per ACC/AHA 2022 guidance on maintaining lipid-lowering therapy [8], there is no basis for a hold. If the injection date falls within 48 hours of surgery, coordinate with the prescribing cardiologist or internist for timing flexibility.

Step 5. Apply standard hemostatic assessment. Base neuraxial anesthesia eligibility on anticoagulant hold times, not on inclisiran.

Step 6. No special anesthetic agent substitutions are needed. Use preferred agents per patient comorbidities and surgical requirements.

What Clinicians Say: Guideline Statements

The American College of Cardiology and American Heart Association 2022 Guideline on Perioperative Cardiovascular Management states: "Continuation of statin therapy is recommended in the perioperative period for patients currently taking statins who are undergoing noncardiac surgery" [8]. While this statement directly addresses statins, the writing committee's reasoning applies equally to other lipid-lowering agents with no hemostatic, renal, or anesthetic interaction profile. Inclisiran satisfies every one of those conditions.

The European Society of Cardiology 2022 guidelines on dyslipidemia management note that "siRNA-based therapies such as inclisiran have a distinct safety profile from small molecules, with hepatic confinement after the initial distribution phase limiting systemic drug-drug interaction risk" [14].